ALNY - Alnylam Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ALNY is currently covered by 26 analysts with an average price target of $358.96. This is a potential upside of $43.21 (13.68%) from yesterday's end of day stock price of $315.75.

Alnylam Pharmaceuticals's activity chart (see below) currently has 413 price targets and 459 ratings on display. The stock rating distribution of ALNY is 25.17% HOLD and 74.83% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 87.37% with an average time for these price targets to be met of 237.66 days.

Highest price target for ALNY is $500, Lowest price target is $268, average price target is $329.08.

Most recent stock forecast was given by TAZEEN AHMAD from BAML on 10-Jul-2025.

Currently out of the existing stock ratings of ALNY, 37 are a HOLD (25.17%), 110 are a BUY (74.83%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$359

$44.06 (13.99%)

$325

3 days ago
(10-Jul-2025)

8/9 (88.89%)

$44.06 (13.99%)

162

Buy

$384

$69.06 (21.93%)

$238

7 days ago
(06-Jul-2025)

7/8 (87.5%)

$59.87 (18.47%)

120

Hold

$333

$18.06 (5.73%)

$287

14 days ago
(29-Jun-2025)

4/6 (66.67%)

$6.91 (2.12%)

31

Buy

$377

$62.06 (19.71%)

$320

18 days ago
(25-Jun-2025)

20/21 (95.24%)

$58.75 (18.46%)

199

Buy

$360

$45.06 (14.31%)

$234

20 days ago
(23-Jun-2025)

4/5 (80%)

$35 (10.77%)

195

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ALNY (Alnylam Pharmaceuticals) average time for price targets to be met?

On average it took 237.66 days on average for the stock forecasts to be realized with a an average price target met ratio 87.37

Which analyst has the current highest performing score on ALNY (Alnylam Pharmaceuticals) with a proven track record?

WHITNEY IJEM

Which analyst has the most public recommendations on ALNY (Alnylam Pharmaceuticals)?

Whitney Ijem works at CANACCORD and has 19 price targets and 10 ratings on ALNY

Which analyst is the currently most bullish on ALNY (Alnylam Pharmaceuticals)?

Patrick Trucchio with highest potential upside - $185.06

Which analyst is the currently most reserved on ALNY (Alnylam Pharmaceuticals)?

Christopher Marai with lowest potential downside - -$240.94

Alnylam Pharmaceuticals in the News

Alnylam Pharmaceuticals' SWOT analysis: broad label approval boosts stock outlook

Alnylam Pharmaceuticals (NASDAQ:ALNY), with a market capitalization of $43.3 billion and impressive year-to-date returns of 41%, has emerged as a leader in RNA interference (RNAi) therapeutics, with a particular focus on treating rare diseases such as transthyretin-mediated amyloidosis (ATTR). According to InvestingPro data, the company maintains strong liquidity with a current ratio of 3.04, positioning...

Q1 2025 Vir Biotechnology Inc Earnings Call

Participants Richard Lepke; Senior Director, Investor Relations; Vir Biotechnology Inc Marianne De Backer; Chief Executive Officer, Director; Vir Biotechnology Inc Mark Eisner; Chief Medical Officer; Vir Biotechnology Inc Jason O’Byrne; Chief Financial Officer; Vir Biotechnology Inc Mika Derynck; Executive Vice President, Therapeutic Area Head Oncology; Vir Biotechnology Inc Gena Wang; Analyst; Barclays Paul Choi; Analyst;...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?